This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Radiation Therapy in Treating Patients Who Are Undergoing Surgery to Remove a Metastatic Brain Tumor

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: April 5, 2005
Last updated: January 9, 2014
Last verified: July 2009

RATIONALE: Specialized radiation therapy that delivers radiation directly to the area where a tumor was surgically removed may kill any remaining tumor cells and cause less damage to normal tissue.

PURPOSE: This phase I/II trial is studying radiation therapy to see how well it works in treating patients who are undergoing surgery to remove a metastatic brain tumor.

Condition Intervention Phase
Metastatic Cancer Procedure: conventional surgery Radiation: intraoperative radiation therapy Phase 1 Phase 2

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study Utilizing the Zeiss INTRABEAM System for the Treatment of a Resected Solitary Brain Metastasis

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Local control rate as measured by MRI with contrast at 1 year

Estimated Enrollment: 62
Study Start Date: April 2004
Estimated Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Detailed Description:



  • Determine the 1-year local control rate in patients undergoing resection of a solitary brain metastasis comprising intraoperative radiotherapy using the INTRABEAM® system.


  • Determine the survival of patients treated with this therapy.
  • Determine distant recurrence of disease in patients treated with this therapy.
  • Determine the toxicity of this therapy in these patients.
  • Determine the quality of life of patients treated with this therapy.

OUTLINE: This is a nonrandomized study.

Patients undergo surgical resection of a brain metastasis. Patients then undergo intraoperative radiotherapy using the INTRABEAM® system.

Quality of life is assessed at baseline and then every 3 months for 2 years.

Patients are followed within 48 hours after surgery, at 1 and 3 months, and then every 3 months for 2 years.

PROJECTED ACCRUAL: A total of 31-62 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Newly diagnosed supratentorial solitary brain metastasis by enhanced MRI or CT scan

    • Resectable disease
    • Histological evidence of metastatic carcinoma by intraoperative pathology
  • No primary lymphoma, germ cell carcinoma, or small cell lung cancer



  • 18 and over

Performance status

  • Karnofsky 70-100%

Life expectancy

  • At least 3 months


  • Not specified


  • Not specified


  • Not specified


  • No uncontrolled hypertension
  • No unstable angina pectoris
  • No uncontrolled dysrhythmias


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No serious infection
  • No other medical illness that would preclude study participation


Biologic therapy

  • Not specified


  • No prior temozolomide or polifeprosan 20 with carmustine implant (Gliadel® wafer) for brain metastasis

Endocrine therapy

  • Not specified


  • No prior brain radiotherapy of any kind, including local or whole brain external beam radiotherapy, brachytherapy, or stereotactic radiosurgery
  • No concurrent external beam radiotherapy to the brain
  • Not planning adjuvant whole brain radiotherapy after study therapy


  • Not specified


  • No other prior conventional or investigational local or systemic agents for brain metastasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00107367

United States, Ohio
Cleveland Clinic Taussig Cancer Center Recruiting
Cleveland, Ohio, United States, 44195
Contact: Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente    866-223-8100      
Sponsors and Collaborators
The Cleveland Clinic
Study Chair: Robert Weil, MD The Cleveland Clinic
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Robert Weil, Cleveland Clinic Taussig Cancer Center Identifier: NCT00107367     History of Changes
Other Study ID Numbers: CDR0000378144
Study First Received: April 5, 2005
Last Updated: January 9, 2014

Keywords provided by National Cancer Institute (NCI):
tumors metastatic to brain

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes processed this record on August 18, 2017